Long term effects of the treatment of polycythemia vera (PV) with recombinant interferon alfa (rIFNα).

被引：0
|
作者：
Silver, RT
Pahuja, M
Klein, J
机构：
[1] New York Presbyterian Hosp, Div Hematol Oncol, New York, NY USA
[2] Weill Cornell Med Ctr, New York, NY USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3205
引用
收藏
页码：741A / 741A
页数：1
相关论文
共 50 条
  • [41] Myopathic syndrome associated with long-term recombinant interferon alfa treatment in 4 patients with skin disorders
    Dippel, E
    Zouboulis, CC
    Tebbe, B
    Orfanos, CE
    ARCHIVES OF DERMATOLOGY, 1998, 134 (07) : 880 - 881
  • [42] LONG-TERM TREATMENT WITH DIFFERENT REGIMENS OF RECOMBINANT INTERFERON-ALFA IN CHRONIC HEPATITIS-C
    PODDA, M
    BATTEZZATI, PM
    ZUIN, M
    BRUNO, S
    GALLOTTI, P
    BORZIO, M
    BORZIO, F
    FORNARI, F
    LANZINI, A
    SALMI, A
    RUSSO, A
    HEPATOLOGY, 1995, 22 (04) : 55 - 55
  • [43] Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival
    Abu Zeinah, Ghaith
    Krichevsky, Spencer
    Jaber, Diana
    Savage, Niamh
    Sosner, Claudia
    Hoberman, Gabriela
    Ritchie, Ellen K.
    Schafer, Andrew I.
    Scandura, Joseph
    Silver, Richard T.
    BLOOD, 2019, 134
  • [44] Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival
    Abu-Zeinah, Ghaith
    Krichevsky, Spencer
    Cruz, Tatiana
    Hoberman, Gabriela
    Savage, Niamh
    Ritchie, Ellen
    Scandura, Joseph
    Silver, Richard T.
    BLOOD, 2020, 136
  • [45] Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
    Yacoub, Abdulraheem
    Mascarenhas, John
    Kosiorek, Heidi
    Prchal, Josef T.
    Berenzon, Dmitry
    Baer, Maria R.
    Ritchie, Ellen
    Silver, Richard T.
    Kessler, Craig
    Winton, Elliott
    Finazzi, Maria Chiara
    Rambaldi, Alessandro
    Vannucchi, Alessandro M.
    Leibowitz, David
    Rondelli, Damiano
    Arcasoy, Murat O.
    Catchatourian, Rosalind
    Vadakara, Joseph
    Rosti, Vittorio
    Hexner, Elizabeth
    Kremyanskaya, Marina
    Sandy, Lonette
    Tripodi, Joseph
    Najfeld, Vesna
    Farnoud, Noushin
    Papaemmanuil, Elli
    Salama, Mohamed
    Singer-Weinberg, Rona
    Rampal, Raajit
    Goldberg, Judith D.
    Barbui, Tiziano
    Mesa, Ruben
    Dueck, Amylou C.
    Hoffman, Ronald
    BLOOD, 2019, 134 (18) : 1498 - 1509
  • [46] Safety of long term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis (AD).
    Schneider, LC
    Baz, Z
    Zarcone, C
    Zurakowski, D
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (01) : 1938 - 1938
  • [47] Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients
    Passamonti, F
    Brusamolino, E
    Lazzarino, M
    Barate, C
    Klersy, C
    Orlandi, E
    Canevari, A
    Castelli, G
    Merante, S
    Bernasconi, C
    HAEMATOLOGICA, 2000, 85 (10) : 1011 - 1018
  • [48] A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera
    Illes, Arpad
    Pinczes, Laszlo Imre
    Egyed, Miklos
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (01) : 3 - 7
  • [49] Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera
    Krecak, Ivan
    Skelin, Marko
    Verstovsek, Srdan
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (05) : 305 - 316
  • [50] Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment
    Qin, Albert
    CLINICAL THERAPEUTICS, 2024, 46 (05) : 439 - 440
12345